Microbix BiosystemsMBXBF -2.90%55 Shareholder Yield % is 0.64% as of Mar. 2026, which is 73% above its 10-year median of 0.37. GuruFocus rates MBXBF with a GF Score™ of 55/100 and a GF Value™ of $0.17 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,299 Biotechnology companies, Microbix Biosystems ranks better than 74.44% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Microbix Biosystems's Shareholder Yield % was 0.64%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Microbix Biosystems Shareholder Yield % Related Terms
Microbix Biosystems Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Microbix Biosystems's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBXBF vs VRTX, REGN, ALNY: Shareholder Yield % Comparison
For the Biotechnology subindustry, Microbix Biosystems's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Microbix Biosystems (MBXBF) has a Shareholder Yield % of 0.64% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Microbix Biosystems and its competitors. This is 73% above median its historical median of 0.37. According to the industry distribution chart, Microbix Biosystems ranks #332 out of 1299 companies in the Biotechnology industry, placing it in the top 25.6%.
Is Microbix Biosystems' Shareholder Yield % too high?
Microbix Biosystems' current Shareholder Yield % of 0.64% is 73% above median its 10-year median of 0.37. Based on the distribution chart, Microbix Biosystems ranks #332 out of 1299 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Microbix Biosystems has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #332 out of 1299 companies for Shareholder Yield %. This puts Microbix Biosystems in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current Shareholder Yield % is 0.64%, which is 73% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.17, compared to a current price of $0.20 — trading 19.9% above its estimated fair value. The current Shareholder Yield % is 0.64%, which is 73% above median its 10-year median of 0.37. Microbix Biosystems' overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current Shareholder Yield % is 0.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (MBXBF) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of $0.20 is trading 19.9% above its estimated GF Value™ of $0.17.
GuruFocus considers Microbix Biosystems to be Modestly Overvalued.
Key valuation signals for MBXBF:
Shareholder Yield %: 0.64% (73% above median its 10-year median of 0.37)
GF Value™: $0.17 vs. price of $0.20 (19.9% above fair value)
No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
55GF Score
Get the complete analysis for MBXBF
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBXBF has been successfully added to your 
